US2019000845A1PendingUtilityA1
Phenyloxadiazole derivatives as pgds inhibitors
Est. expiryOct 8, 2029(~3.2 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 37/08A61P 5/00A61P 29/00A61P 27/02A61P 11/00A61P 11/02A61P 11/06C07D 217/06A61K 31/506A61K 31/495C07D 413/14C07D 271/07C07D 271/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
Claims
exact text as granted — not AI-modified1 . A compound of formula (I):
wherein
R1 is hydrogen or C 1 -C 6 alkyl;
R2 is hydrogen, halogen or C 1 -C 3 alkyl; and
R3 is hydroxyalkyl;
or a pharmaceutically acceptable salt thereof.
2 - 24 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.